You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>IMS</strong> COM PANY PRO FILES TAKEDA<br />
Research Pipeline for Takeda<br />
R&D Profile<br />
Compound Code Class Phase<br />
drug delivery system, modified<br />
release dexlansoprazole TAK 390MR A2B2 Approved<br />
febuxostat TMX 67, TEI 6720 M4A Approved<br />
alogliptin benzoate SYR 322 A10N1 Filed<br />
idebenone SNT MC17 N6D, N7X, M5X Filed<br />
panitumumab AMG 706 L1X3 Filed<br />
pioglitazone + metformin<br />
extended-release — A10K3 Filed<br />
asoprisnil J 867 G2X9 III<br />
azilsartan + pioglitazone — C9C III<br />
azilsartan medoxomil TAK 491 C9C III<br />
bis-aryl-sulphanyl amine LU AA21004 N6A9 III<br />
cetilistat ATL 962 A8A III<br />
ilaprazole IY 81149 A2B2 III<br />
motesanib AMG 706 L1X4 III<br />
pegylated erythropoietin<br />
receptor agonist AF 37702 B3X III<br />
repaglinide — A10B9 III<br />
resatorvid TAK 242 L4A, V3X III<br />
vedolizumab MLN 0002 A7E III<br />
venlafaxine WY 45030 N6A5, N5C, N7X III<br />
antirheumatic TAK 783 M1C II<br />
azilsartan TAK 536 C9C II<br />
bis-aryl-sulphanyl amine LU AA24530 N6A9 II<br />
ddp-iv inhibitor SYR 472 A10N1 II<br />
diabetic neuropathy therapy TAK 428 N7X II<br />
epa/dha agent TAK 085 C10A9 II<br />
epetirimod TAK 851, R 851 J5B II<br />
factor xa inhibitor TAK 442 B2C1 II<br />
G2 checkpoint abrogater CBP 501 L1X1 II<br />
GnRH analogue, Norwood<br />
Immunology/Takeda — L2A3 II<br />
insulin sensitizer TAK 379 A10X II<br />
insulin sensitizer TAK 875 A10X II<br />
lestaurtinib CEP 701 L1X4 II<br />
MAb, CCR2, Millennium MLN 1202 L4A, N7X, C6A II<br />
P38 MAP kinase Inhibitor TAK 715 M1C II<br />
PHN therapy TAK 583 N7X II<br />
tandutnib MLN 0518 L1X4 II<br />
advanced malignancies therapy MLN 4924 L1X9 I<br />
advanced malignancies therapy MLN 8054 L1X4 I<br />
advanced malignancies therapy MLN 8237 L1X4 I<br />
ARB for hypertension TAK 591 C9C I<br />
cancer therapy MLN 2238 L1X9 I<br />
CCR5 antagonist — J5C9 I<br />
conatumumab AMG 655 L1X3, T1G I<br />
ddp-iv inhibitor TAK 100 A10N1 I<br />
inflammatory disease therapy MLN 0415 A7E, R3X, N7X I<br />
inflammatory disease therapy MLN 3701 M1C I<br />
injectable gnrh modulator TAK 683 H4X, L1X9 I<br />
© 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 55
Change language